Check out BIOCON Stock Reports on The Economic Times. Complete detailed Stock Analysis for BIOCON, BIOCON Earnings Indicators ...

Biocon delivered a robust Q2 FY26 with 20% YoY operating revenue growth to INR 4,296 crores, led by biosimilars (up 25% YoY) and generics (up 24% YoY). Margin expansion, debt reduction, and successful ...

Yes Bank, PI Industries, MRF, Swiggy, Biocon, NMDC, Tube Investments of India, Vishal Mega Mart, Voltas and Max Financial ...

The Great Eastern Shipping Company Limited (NSE: GESHIP) and Biocon Limited (NSE: BIOCON), Enviro Infra Engineers (NSE: EIEL) ...

India must move beyond its success in generic medicines and build an innovation-led pharmaceutical industry, according to ...

Biocon Limited has entered into a global patent settlement and license agreement with Genentech, successfully securing the ...

Biocon Limited has entered into a global patent settlement and licence agreement with Genentech, securing licensed launch ...

India, Oct. 14 -- Max Healthcare Institute Limited ...

Roche's Genentech has settled a US lawsuit against Indian biopharmaceutical company Biocon over its ​proposed biosimilar of ...

Biocon reaches global patent settlement with Genentech for its breast cancer biosimilar, Pebrilzo. Launches planned for EU/UK ...

The global patent settlement allows Biocon to launch its Perjeta biosimilar Pebrilzo in the EU and UK from the first quarter ...